Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356724 | 0.86 | MEN1 (0.44) | CYP2C19FAAHEPHX2MEN1KMT2A | |
| SCHEMBL7676676 | 0.86 | TSHR (0.40) | CYP2C19KMT2ATSHRRECQLPOLB | |
| SCHEMBL27410515 | 0.85 | FAAH (0.46) | FAAHMEN1KMT2ATSHRRECQL | |
| SCHEMBL11908564 | 0.84 | ALDH1A1 (0.48) | CYP2C19FAAHEPHX2MEN1KMT2A | |
| SCHEMBL15552174 | 0.84 | ALDH1A1 (0.48) | CYP2C19FAAHEPHX2MEN1KMT2A | |
| SCHEMBL27075765 | 0.84 | FAAH (0.45) | CYP2C19FAAHMEN1KMT2ATSHR | |
| SCHEMBL27075768 | 0.84 | FAAH (0.45) | CYP2C19FAAHMEN1KMT2ATSHR | |
| SCHEMBL27075776 | 0.84 | FAAH (0.45) | CYP2C19FAAHMEN1KMT2ATSHR | |
| SCHEMBL3273924 | 0.83 | FAAH (0.51) | FAAHEPHX2MEN1KMT2ATSHR | |
| SCHEMBL10140852 | 0.81 | FAAH (0.59) | FAAHEPHX2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | CYP2C19 2166/4885FAAH 1633/4885EPHX2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.